



## **HJV mutations causing hemochromatosis: variable phenotypic expression in a pair of twins**

by Akhila Vadivelan, Sarah Zhang, Daniel N. Srole, Elizabeth A. Marcus, George Carvalho Neto, Elizabeta Nemeth, Tomas Ganz, and Satiro De Oliveira

*Received: August 24, 2023.*

*Accepted: February 28, 2024.*

*Citation: Akhila Vadivelan, Sarah Zhang, Daniel N. Srole, Elizabeth A. Marcus, George Carvalho Neto, Elizabeta Nemeth, Tomas Ganz, and Satiro De Oliveira. HJV mutations causing hemochromatosis: variable phenotypic expression in a pair of twins.*

*Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284134 [Epub ahead of print]*

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.*

*E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.*

**Running heads:** *HJV* mutations causing hemochromatosis: variable phenotypic expression in a pair of twins.

Akhila Vadivelan<sup>1,2</sup>, Sarah Zhang<sup>3</sup>, Daniel N. Srole<sup>2</sup>, Elizabeth A. Marcus<sup>4</sup>, George Carvalho Neto<sup>5</sup>, Elizabeta Nemeth<sup>2</sup>, Tomas Ganz<sup>2,6</sup>, Satiro De Oliveira<sup>1</sup>

<sup>1</sup>Division of Pediatrics, Division of Hematology/Oncology, UCLA, Los Angeles

<sup>2</sup>Center for Iron Disorders, Department of Medicine, UCLA, Los Angeles

<sup>3</sup>Division of Pathology, UCLA, Los Angeles

<sup>4</sup>Division of Pediatric, Pediatric Gastroenterology, Hepatology, and Nutrition, UCLA, Los Angeles

<sup>5</sup>Corporate Authorship -Undiagnosed Diseases Network, Institute for Precision Health

<sup>6</sup>Division of Medicine and Pathology, UCLA, Los Angeles

**Author Contribution:**

AV- preparation of manuscript and figures

SZ- preparation of pathology images

DS- revision of manuscript and brainstorm discussion

GC- Performed whole genome sequence.

EM-revision of manuscript and brainstorm discussion

EN- revision of manuscript and brainstorm discussion

TG- revision of manuscript and brainstorm discussion

SD- revision of manuscript and brainstorm discussion

**Corresponding author:** Akhila Vadivelan. Email: [av.akhila@gmail.com](mailto:av.akhila@gmail.com)

**Conflict of Interest:** None from any of the authors.

**Data sharing:** Data can be accessed with the references, tables and figures submitted as part of the manuscript.

**Funding:** This work was partially supported by the UCLA California Center for Rare Disease of the Institute for Precision Health and by National Institutes of Health grant U01NS134356 awarded to the UCLA Clinical Site of the Undiagnosed Diseases Network.

Hemochromatosis is a genetic condition characterized by excessive intestinal iron absorption leading to systemic iron overload. Hemochromatosis is caused by a deficiency of hepcidin, or resistance to the effects of hepcidin. The mutations that cause hepcidin deficiency affect genes that regulate hepcidin transcription, or the hepcidin gene itself. Homozygous C282Y mutation in *HFE* is the most common cause of hemochromatosis, however mutations in other genes, including *HJV*, *HAMP*, and *TFR2*<sup>1</sup>, can also cause hemochromatosis. Resistance to hepcidin is caused by certain autosomal dominant mutations in *SLC40A1*, the gene encoding the hepcidin receptor and iron transporter ferroportin<sup>1</sup>. Homozygous or compound heterozygous *HJV* mutations are the most common cause of juvenile hemochromatosis (JH) with an autosomal recessive pattern of inheritance. JH is characterized by early onset severe iron overload before age 30 leading to liver damage, cardiomyopathy, diabetes, arthropathy, and hypogonadism<sup>2</sup>. *HJV* codes for the hemojuvelin protein, a bone morphogenetic protein co-receptor, which is essential for adequate hepcidin production in response to iron<sup>3</sup>. Among several mutations identified, *HJV*pG320V is the most common mutation worldwide. Here we report a case of fraternal twin girls with similar *HJV* mutations but highly discordant severity of iron overload after obtaining parental consent as part of the Undiagnosed Disease Network.

The dizygotic twin girls were born at 32 weeks of gestation to a primigravida mother. They were conceived with intrauterine insemination. Pregnancy was complicated by placenta previa and placenta accreta in twin B. A C-section was performed as twin B had intrauterine growth restriction (IUGR). Family history includes mother with SLE and Sjogren's syndrome and father who had a benign neuroendocrine tumor.

Twin A weighed 1.8 kg at birth, had a single umbilical artery, and stayed in the neonatal intensive care unit (NICU) for 10 days to establish feeding. She was discharged with ptosis as the only noted abnormality. Since then, she has been meeting all her developmental milestones and growing appropriately. At age 7, the patient had axillary and pubic hair, was evaluated for precocious puberty. Patient was using lavender lotions and soaps which apparently contributed to premature adrenarche, and the rest of the workup for precocious puberty was unremarkable. Incidentally, the patient was found to have elevated liver enzymes AST 101 U/L (age-appropriate normal range 13-62 U/L), ALT 183 U/L (8-70 U/L), alkaline phosphatase 356 U/L (145-335 U/L). She had a positive ANA 1/640 titer, homogeneous pattern. Due to persistent elevation in liver enzymes, a liver biopsy was performed, which revealed moderate iron deposition with focal bridging fibrosis (etiology of fibrosis is unclear), a hepatic iron concentration of 17362 µg/g/dry weight of liver tissue (200-1800 µg/g). **Figure 1**. Iron studies showed ferritin of 1763 ng/mL (8-180 ng/mL), serum iron 308 mcg/dL (27-164 mcg/dL), TIBC 328 mcg/dL (271-448 mcg/dL), serum transferrin 215 mg/dL (188-341 mg/dL), and transferrin saturation of 94%. Genetic testing for hemochromatosis revealed pathogenic compound heterozygous *HJV* mutations and heterozygosity for the H63D *HFE* mutation as listed in **Table 1(A)**. Patient opted to be on iron chelation instead of phlebotomy, hence started on deferasirox 10 mg/kg/day. MRI of the abdomen performed three months after starting chelation showed diffuse hepatic iron overload with estimated iron concentration of 5.9 mg Fe per 1 g dry liver. Liver enzymes (AST 52 U/L, ALT 66 U/L), serum ferritin (1480 ng/mL) and transferrin saturation (54%) showed a decreasing trend.

Twin B weighed 680 g at birth and spent 3 months in the NICU, course was complicated by chronic lung disease, feeding intolerance, failure to thrive, and astigmatism. Chromosomal microarray study was normal. At 8 months, she was diagnosed with infantile spasms and brain MRI revealed pachygyria. She was then tested for *IGF1R* and *PAPPA2* mutations through next generation sequencing, but no abnormality was found. She was diagnosed with gastric esophageal reflux disease and was treated with

proton pump inhibitors (PPI). She also had poor weight gain of 400-900 g per year despite adequate calorie intake by mouth. Patient has received zinc, copper, and folate supplementation during infancy. A whole exome sequencing was performed. A heterozygous c.636\_638delAGA, pGlu215del variant of uncertain significance in the BUB1B gene was identified. Variants in this gene are associated with autosomal recessive mosaic variegated aneuploidy (MVA) syndrome 1. At age 7, serum ferritin was 196 ng/dL, serum iron 261 mcg/dL, TIBC <283 mcg/dL, and serum transferrin 239 mg/dL, transferrin saturation 94 %. Genetic testing revealed the same heterozygous HJV mutations and heterozygosity for the H63D HFE mutation as in her sister. MRI of the abdomen was not performed as it was not clinically indicated. She has no clinical signs of iron overload currently. Laboratory parameters of the twins are in **Table 1(B)**.

Iron overload in HJV associated JH (HJV-JH) develops at an early age, with the mean age at diagnosis of 24 years. The sex distribution is equal in HJV-JH<sup>4</sup>. HJVpGy320Val and HJV Leu101Pro are the most common mutations in Caucasians<sup>5</sup>. HFE-associated hemochromatosis is inherited in an autosomal recessive pattern and p. Cys282Tyr in HFE is the most common pathogenic substitution in Caucasians. Both girls have an HFE mutation, with variant c.187C>G p. His63Asp (H63D) in addition to the HJV mutations. The H63D mutation is mild, and a single copy has not been known to cause any iron dysregulation. The interaction between H63D in HFE and HJV has not been established. Prior to the discovery of the HFE gene but after the linkage of the common form of hemochromatosis to human leucocyte antigen (HLA) was already established, Crawford et al reported concordance in hepatic iron concentration among siblings of same sex with genetic hemochromatosis unless one of the siblings had definite reason for blood loss or discordance in HLA status<sup>6</sup>. Piling et al report that common genetic variants that influence iron in the general population may help in estimating prognosis and treatment planning in patients with HFEpC282Y homozygous mutations<sup>7</sup>. Although twin A and twin B have the same known hemochromatosis (HJV) mutations, twin B has normal serum ferritin level and no clinical signs of iron overload. Twin B has no history of bleeding or blood donation. She has been maintaining hemoglobin >11 since discharge from the NICU. Fraternal twins share only half their genome, so it is possible that discordance in yet unknown genetic modifiers cause the phenotypic difference.

We measured serum hepcidin levels in both twins. Twin A has a low serum hepcidin of 7.7 ng/mL (normal range 4.4-47.3 ng/mL) despite elevated ferritin, and hepcidin to ferritin (H: F) ratio of 0.018 indicating classical hemochromatosis phenotype<sup>8</sup>. Twin B has a serum hepcidin level of 12.3 ng/mL and H: F ratio of 0.072, four-times higher than twin A. The level of hepcidin in Twin B is inappropriately low considering the high serum transferrin saturation (>50%). It is unclear why the patient has high transferrin saturation but no evidence of elevated iron stores (ferritin 170 ng/mL). Iron utilization appears normal as hemoglobin (13.4g/dL) is within the normal range. Twin B has higher mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC), by ~10% consistently (**Table1 (B)**). This may indicate that she is utilizing iron for erythropoiesis at a higher rate than her sister, however their reticulocyte count is similar.

Twin B has a BUB1B mutation which is associated with MVA syndrome. Based on exome sequencing, she appears to be a carrier for this condition. We pursued additional testing, a sensitive genome-wide method to assess aneuploidy from blood DNA for which whole genome sequence was generated. There was no evidence of any aneuploidy. There are no reports of any relationship between BUB1B mutation and iron metabolism. Twin B however has a few features of the MVA, such as IUGR, slow post-natal growth, shorter than average stature, and pachygyria with seizures. Currently, twin B weighs 15.6kg at 8 years of age, less than the 1 percentile (compared to twin A who is 39 kg at 91<sup>st</sup> percentile). It is likely

that Twin B's chronic malnutrition has contributed to having normal serum iron and ferritin levels despite having high transferrin saturation levels (>50%). She may be absorbing iron at a higher rate than other nutrients because of her hemochromatosis mutations, which allows maintaining iron homeostasis and erythropoiesis at a normal level despite malnutrition. In contrast, the patient has been taking zinc supplements. Serum zinc lowest at 49 µg/dL at age 4, maintains in the range of 62.6-98.6 µg/dL with zinc supplements (normal 60-120 µg/dL).

PPIs are known to limit iron absorption<sup>9,10</sup>, thus it is possible that twin B absorbed less iron than what would be expected based on the hemochromatosis mutations. However, patient stopped taking PPI for the last two months and the iron studies have not changed appreciably (serum iron 233 vs 250 mcg/dL, TIBC <255 vs <272 mcg/dL and ferritin 129 vs 170 ng/mL). Longer observation is needed to make a more meaningful conclusion regarding any effect of PPI on iron parameters since she been taking them for the last 8 years.

We describe for the first time a severe case of juvenile hemochromatosis presenting with classical clinical features in contrast to her twin sister with the same mutations in the HJV gene with no signs of iron overload. In addition to the recognized hemochromatosis genes, other genetic and nutritional factors may modulate the severity of iron overload in hemochromatosis.

## REFERENCES

1. Santos PC, Dinardo CL, Cançado RD, Schettert IT, Krieger JE, Pereira AC. Non-HFE hemochromatosis. *Rev Bras Hematol Hemoter.* 2012;34(4):311-316.
2. Griffiths WJH, Besser M, Bowden DJ, Kelly DA. Juvenile haemochromatosis. *Lancet Child Adolesc Health.* 2021;5(7):524-530.
3. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. *Blood.* 2005;106(8):2884-2889.
4. Sandhu K, Flintoff K, Chatfield MD, et al. Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease. *Blood.* 2018;132(1):101-110.
5. Kong X, Xie L, Zhu H, et al. Genotypic and phenotypic spectra of hemojuvelin mutations in primary hemochromatosis patients: a systematic review. *Orphanet J Rare Dis.* 2019;14(1):171.
6. Crawford DH, Halliday JW, Summers KM, et al. Concordance of iron storage in siblings with genetic hemochromatosis: evidence for a predominantly genetic effect on iron storage. *Hepatology.* 1993(5):833-837.
7. Pilling LC, Atkins JL, Melzer D. Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort. *Hepatology.* 2022;76(6):1735-1745.
8. Zaman BA, Ibrahim SA. Hepcidin-to-Ferritin Ratio as an Early Diagnostic Index of Iron Overload in  $\beta$ -Thalassemia Major Patients. *Hemoglobin.* 2022 ;46(2):106-113.
9. Hirofumi Hamano, Takahiro Niimura, Yuya Horinouchi, et al. Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. *Toxicol Lett.* 2020;318:86-91.
10. Kani HT, Gündüz F. Should we use proton pump inhibitors as an add-on treatment in hereditary hemochromatosis? *Turk J Gastroenterol.* 2018;29(2):253.

Table 1: Laboratory findings in the twins

**(A) Genetic findings in the twins.**

**(B) Hematological and biochemical parameters in the twins**

Table 1  
(A)

	Gene	Zygosity	Coding Change	Frequency	Classification	Inheritance
<b>TWIN A</b>	HFE	Heterozygous	c.187C>G p.His63Asp	14% European non- Finnish	Risk	
	HJV	Heterozygous	c.302 T>C p.Leu101Pro	0.00093 % European non- Finnish	Pathogenic	
	HJV	Heterozygous	c.959 G>T, p.Gly320 Val	0.039% European non- Finnish	Pathogenic	
<b>TWIN B</b>	BUB1B	Heterozygous	p.Glu215del chr15:g.40475962_404 75964delAAG		Uncertain significance	Mother
	HFE	Heterozygous	c.187C>G p.His63Asp	14% European non- Finnish	Risk	
	HJV	Heterozygous	c.302 T>C p.Leu101Pro	0.00093 % European non- Finnish	Pathogenic	
	HJV	Heterozygous	c.959 G>T, p.Gly320 Val	0.039% European non- Finnish	Pathogenic	

(B)

	At the time of diagnosis		3 months after chelation for twin A		11 months after chelation for twin A and 2 months after stopping PPI for twin B	
	TWINA	TWIN B	TWIN A	TWIN B	TWIN A	TWIN B
Hemoglobin(g/dL)	13.0	14.4	13	13.0	12.8	13.4
Hematocrit (%)	38.9	41	38.9	36.4	39.2	38.2
Red blood cell count ( $\times 10^6$ /microL)	4.45	4.37	4.31	3.90	4.45	4.20
Mean corpuscular volume (fL)	87.4	93.8	86.3	93.3	88.1	91
Mean corpuscular hemoglobin (pg)	29.2	33	29.2	33.3	28.8	31.9
Mean corpuscular hemoglobin concentration(g/dL)	33.4	36.7	40.8	43.5	32.7	35.1
Red cell distribution width (%)	12.8	12.1	12.8	13	12.3	12
Reticulocyte count (%)	2.29	-	1.59	3.82	1.96	2.0
Absolute retic count ( $\times 10^6$ /microL)	0.10	-	0.07	0.15	0.09	0.09
Platelet count ( $\times 10^3$ /microL)	367	260	367	231	315	204
White blood cell count ( $\times 10^3$ /microL)	6.68	9.79	6.68	7.91	6.54	5.75
Ferritin (ng/dL)	1763	196	1480	129	416	170
Serum iron (mcg/dL)	308	261	305	233	327	250
Iron binding capacity (mcg/dL)	328	<283	603	<255	588	<272
Transferrin saturation (%)	94	77.42	51	82.18	56	Unable to calculate
Aspartate transaminase (AST)(U/L)	148	25	52	27	44	27
Alanine transaminase (ALT) (U/L)	262	17	66	13	37	17
Hepcidin levels (ng/mL)	-	-	-	-	7.7	12.3



**LEGEND:**


Figure 1: Liver biopsy of twin A

**(A) Perl's Prussian blue iron stain,200x:** There is moderate hemosiderin deposition predominantly within the hepatocytes. Scattered iron laden Kupffer cells are present.

**(B) (B)Trichome stain,100x:** Bridging fibrosis highlighted in blue.

Figure 1

(A)



(B)

